RP Management’s Cytokinetics CYTK Stock Holding History

RP Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-980,392	Closed	-$39.4M	–	3
2025 Q1	$39.4M	Hold	980,392	–	–	28.38%	2
2024 Q4	$51.8M	Hold	980,392	–	–	22.73%	2
2024 Q3	$51.8M	Hold	980,392	–	–	22.73%	2
2024 Q2	$53.1M	Buy	+980,392	New	+$59.2M	29.71%	2
2021 Q2	–	Sell	-875,656	Closed	-$20.4M	–	5
2021 Q1	$20.4M	Hold	875,656	–	–	7.65%	4
2020 Q4	$18.2M	Hold	875,656	–	–	5.58%	4
2020 Q3	$19M	Hold	875,656	–	–	2.84%	5
2020 Q2	$20.6M	Hold	875,656	–	–	3.99%	5
2020 Q1	$10.3M	Hold	875,656	–	–	3.21%	5
2019 Q4	$9.29M	Hold	875,656	–	–	2.1%	5
2019 Q3	$9.96M	Hold	875,656	–	–	6.38%	3
2019 Q2	$9.85M	Hold	875,656	–	–	6.04%	3
2019 Q1	$7.08M	Hold	875,656	–	–	3.54%	3
2018 Q4	$5.53M	Buy	+875,656	New	+$6.42M	3.79%	3

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RP Management's CYTK Position: Q2 2025 in Review

RP Management sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 980,392 shares — an estimated $39.4M sold.

RP Management first reported a position in CYTK in Q4 2018 and held it in 14 quarters. The position peaked at $53.1M in Q2 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

RP Management reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
RP Management sold 980,392 Cytokinetics shares in Q2 2025, an estimated $39.4M.
RP Management first reported a position in Cytokinetics in Q4 2018 and held it in 14 quarters.
RP Management's Cytokinetics position peaked at $53.1M in Q2 2024.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on RP Management's 13F filing for Q2 2025.